Therapeutic areas
and products

Our relationship with dermatology began 15 years ago when we offered for the first time in Spain a new solution to treat the skin of patients with psoriasis, a condition affecting 2.3% of the Spanish population. Keep reading...

With the line of hospital products our responsibility for the care of patients is not only therapeutic. It is also social. That is why we focus our activity on hospital medicines for oncology, neurosurgery, urology and drug dependence. The national health system offers the possibility of exclusive and differentiated hospital drugs. Keep reading...

A significant number of patients have to deal with pathologies involving pain. It is estimated that one in six Spanish people (17%) suffer from chronic pain. At Gebro Pharma we treat nearly five million suffering patients. Pain is also one of the main factors that lead patients to consult primary care services. Keep reading...

In early 2015 Gebro Pharma breathed new air into the market by inaugurating a new therapeutic area: the respiratory area. The franchise opened its doors with a product that assisted patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD). Tovanor® Breezhaler® arrived and began to tackle a disease that affects more than 10% of the population, and therefore has an enormous socio-health impact. Keep reading...

Our relationship with dermatology began 15 years ago when we offered for the first time in Spain a new solution to treat the skin of patients with psoriasis, a condition affecting 2.3% of the Spanish population. Keep reading...

Our passion for Urogynecology is now more than 10 years old. With a wide variety of products included in our urological and gynaecological portfolio, urogynaecology already forms part of the DNA of Gebro Pharma.
The urology franchise is one of our strategic pillars and our commitment to urogynaecological patients makes it an area with a long future ahead of it in our company. Keep reading...